Evidence map›Paper›PMID 9502080›Full record

ArticleClinical & experimental metastasis1998

Over-expression of human CD44s in murine 3T3 cells: selection against during primary tumorigenesis and selection for during micrometastasis.

P Kogerman, M S Sy, L A Culp

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. CD44 cell adhesion molecules.Molecular pathology : MP · 1999
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

P KogermanDepartment of Molecular Biology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
M S Sy
L A Culp
Case Western Reserve University · US

Funding

FIBRONECTIN--PROTEOGLYCAN BINDING IN ADHESION SITESR01CA027755 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CULP, LLOYD A · 1985 to 1993
–
CD44 AND TUMOR GROWTH AND METASTASISR55CA060469 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI SY, MAN-SUN M · 1993 to 1993
–
NCI NIH HHS CA27755NCI NIH HHS CA60469
6 · The paper itself

Abstract

Human CD44 standard isoform (hCD44s) cDNA regulated by a high-expressing promoter was transfected into Balb/c 3T3 cells and the tumorigenic and metastatic capacities of the transfectants were investigated in nude mice at the subcutaneous site. One of three transfectants was tumorigenic. hCD44s expression was lost in the cells of large primary tumors using this tumorigenic clone. These tumors were extremely aggressive giving overt metastases and micrometastases to several sites including mesentery, stomach, liver, diaphragm, pancreas and lung. Micrometastatic cells re-expressed hCD44s, consistent with its importance for early steps in the metastatic cascade. hCD44s was not expressed in overt metastases; most probably the expression was lost during the outgrowth of micrometastases into overt metastatic tumors. Thus hCD44s expression in murine 3T3 cells does induce tumorigenicity in select cases, is not compatible with aggressive outgrowth of primary or secondary tumors, and is advantageous for early steps in metastatic spread. These results suggest that CD44s is an example of a novel type of 'metastasis' molecule that is disadvantageous for tumor growth and is only transiently advantageous during metastatic spreading of tumor cells to distant organs.

Indexed as

Neoplasm Metastasis3T3 CellsAnimalsCell Transformation, NeoplasticDisease ProgressionFlow CytometryHumansHyaluronan ReceptorsMiceMice, Inbred BALB CMice, NudeTransfectionHyaluronan Receptors

Identifiers

PMID9502080
OpenAlexW310605293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.